Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low – What’s Next?

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $20.78 and last traded at $20.81, with a volume of 62922 shares traded. The stock had previously closed at $21.33.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, UBS Group assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.22.

Celldex Therapeutics Stock Down 2.8 %

The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -8.10 and a beta of 1.60. The stock has a fifty day moving average of $24.24 and a two-hundred day moving average of $29.24.

Institutional Trading of Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 878 shares during the period. KBC Group NV raised its stake in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the period. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the fourth quarter worth about $81,000. AlphaQuest LLC boosted its stake in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in shares of Celldex Therapeutics during the fourth quarter valued at approximately $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.